Physician profile
Peter E Hendricks
NPI 1528752706
$1,783.81
in general payments reported to CMS, 2019-2025
16 companies · $944 in 2025
The $944 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $840 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $348.56 | 2024-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $275.03 | 2024-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $182.72 | 2024-2025 | Wainua, Farxiga |
| Abbott Laboratories | $175.14 | 2025 | Cardiomems |
| Lexicon Pharmaceuticals, INC. | $166.88 | 2024 | Inpefa |
| Scpharmaceuticals INC. | $151.18 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $89.99 | 2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.46 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $87.04 | 2024-2025 | |
| Amgen INC. | $64.03 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $53.13 | 2025 | |
| Bridgebio Pharma, INC. | $38.49 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $18.89 | 2024 | Xarelto |
| Daiichi Sankyo INC. | $16.01 | 2024 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $15.70 | 2024 | Arcalyst |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.56 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.